# ZBTB9

## Overview
ZBTB9 is a gene that encodes the zinc finger and BTB domain-containing protein 9, which is a member of the zinc finger protein family characterized by the presence of a BTB domain and C2H2 zinc finger domains. The protein plays a significant role in transcriptional regulation by facilitating protein-protein interactions and specific DNA binding. It is involved in various cellular processes, including the regulation of adipocyte biology and NF-κB signaling. ZBTB9 acts as a positive regulator of PPARγ activity in mature adipocytes, influencing glucose homeostasis and insulin sensitization, while also serving as a negative regulator during early adipogenesis by modulating RB-E2F signaling. Clinically, ZBTB9 has been implicated in liver hepatocellular carcinoma, where its overexpression is associated with tumor progression and poor prognosis, making it a potential prognostic biomarker and therapeutic target (Sugiyama2022CFPPiD; Xu2024Cellstate; Zhang2022Identification).

## Structure
ZBTB9 is a protein characterized by the presence of a BTB (Broad-Complex, Tramtrack, and Bric-à-brac) domain and two C2H2 zinc finger domains. The BTB domain is involved in protein-protein interactions, facilitating the formation of homo- and heterodimers, and is highly conserved between mice and humans, with a 96% identity in these domains (Xu2024Cellstate). The zinc finger domains are responsible for specific DNA sequence recognition and binding, playing a crucial role in transcriptional regulation (Costoya2007Functional).

The protein may undergo post-translational modifications, such as phosphorylation, which can influence its function and interactions (Xu2024Cellstate). Although the specific three-dimensional conformation of ZBTB9 is not detailed in the available literature, its structural domains suggest a role in transcriptional regulation through interactions with other proteins and DNA (Xu2024Cellstate).

ZBTB9 has been identified as part of a protein complex involved in regulating PPARγ signaling in adipocytes, indicating its functional significance in cellular processes (Xu2024Cellstate). The protein's interaction with other components of the PPARγ complex suggests a potential quaternary structure involving multiple protein partners (Xu2024Cellstate).

## Function
ZBTB9 is a gene that encodes a protein involved in the regulation of adipocyte biology, particularly through its interaction with PPARγ signaling. In mature adipocytes, ZBTB9 acts as a positive regulator of PPARγ activity by interacting with the PPARγ/RXRα/ZFP407 complex, enhancing the expression of PPARγ target genes. This interaction is crucial for the proper function of mature adipocytes, influencing glucose homeostasis and insulin sensitization (Xu2024Cellstate).

Conversely, ZBTB9 serves as a negative regulator during the early stages of adipogenesis. It modulates RB-E2F signaling, which is essential for early adipocyte differentiation. ZBTB9 deficiency leads to increased E2F activity, resulting in the upregulation of adipogenic genes, including Pparg, Adipoq, Fabp4, and Glut4, thereby promoting adipogenesis (Xu2024Cellstate).

The dual role of ZBTB9 in adipocyte differentiation and function highlights its importance in metabolic processes and its potential implications in metabolic diseases such as obesity and type 2 diabetes. The gene's function is conserved across species, as similar regulatory roles have been observed in both mouse and human cell models (Xu2024Cellstate).

## Clinical Significance
The ZBTB9 gene has been identified as having significant clinical implications in liver hepatocellular carcinoma (LIHC). Overexpression of ZBTB9 is associated with tumor progression and poor prognosis in LIHC patients. This overexpression is linked to the activation of cell cycle pathways, DNA repair mechanisms, and immune dysregulation, contributing to tumorigenesis (Zhang2022Identification). Genetic alterations in ZBTB9, such as mutations and amplifications, are observed in LIHC, with a frequency of 2.69% among patients. These alterations, along with promoter hypomethylation, may lead to abnormal expression of ZBTB9, further contributing to cancer development (Zhang2022Identification).

High levels of ZBTB9 expression correlate with shorter overall survival and disease-specific survival in LIHC patients, making it a potential prognostic biomarker (Zhang2022Identification). The gene's expression is also negatively correlated with immune cell infiltration in the tumor microenvironment, suggesting that high ZBTB9 levels may result in a 'cold' tumor immune microenvironment, which could affect the efficacy of immune checkpoint inhibitors (Zhang2022Identification). These findings highlight ZBTB9 as a promising therapeutic target and biomarker for assessing treatment response in LIHC.

## Interactions
ZBTB9, a member of the zinc finger and BTB domain-containing protein family, is involved in various protein-protein interactions. The CF-PPiD technology has identified ZBTB9 as a protein that interacts with IκBα, a key component in the NF-κB signaling pathway. This interaction was detected through proximity biotinylation, which allows for the identification of protein interactions that might be missed by traditional methods like immunoprecipitation (Sugiyama2022CFPPiD). The interaction between ZBTB9 and IκBα suggests a potential role for ZBTB9 in modulating NF-κB signaling, although ZBTB9 did not affect RelA transcriptional activity under normal or TNF-α stimulated conditions (Sugiyama2022CFPPiD).

In the context of liver hepatocellular carcinoma (LIHC), ZBTB9 has been shown to interact with several proteins identified using the STRING tool. These include WDR46, PFDN6, VPS52, SLC39A7, COL11A2, HSD17B8, PHF1, RGL2, CUTA, and TAPBP. These interactions are associated with processes such as spliceosome function, mRNA binding, and chromatin organization, which are crucial for cell proliferation and tumor progression (Zhang2022Identification).


## References


[1. (Sugiyama2022CFPPiD) Shusei Sugiyama, Kohdai Yamada, Miwako Denda, Satoshi Yamanaka, Satoshi Ozawa, Ryo Morishita, and Tatsuya Sawasaki. Cf-ppid technology based on cell-free protein array and proximity biotinylation enzyme for in vitro direct interactome analysis. Scientific Reports, June 2022. URL: http://dx.doi.org/10.1038/s41598-022-14872-w, doi:10.1038/s41598-022-14872-w. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-14872-w)

[2. (Costoya2007Functional) J. A. Costoya. Functional analysis of the role of pok transcriptional repressors. Briefings in Functional Genomics and Proteomics, 6(1):8–18, March 2007. URL: http://dx.doi.org/10.1093/bfgp/elm002, doi:10.1093/bfgp/elm002. This article has 84 citations.](https://doi.org/10.1093/bfgp/elm002)

3. (Xu2024Cellstate) Cell-state dependent regulation of PPARγsignaling by ZBTB9 in adipocytes. This article has 1 citations.

[4. (Zhang2022Identification) Zhenshan Zhang, Leilei Wu, Juan Li, Jiayan Chen, Qi Yu, Hui Yao, Yaping Xu, and Liang Liu. Identification of zbtb9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in liver hepatocellular carcinoma. Journal of Translational Medicine, December 2022. URL: http://dx.doi.org/10.1186/s12967-022-03790-0, doi:10.1186/s12967-022-03790-0. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12967-022-03790-0)